Matching articles for "tocilizumab"
Issue 1733 · July 21, 2025
Upadacitinib (Rinvoq) for Giant Cell Arteritis

The oral Janus kinase (JAK) inhibitor upadacitinib ( Rinvoq – Abbvie) has been approved by the FDA for treatment of giant cell arteritis. Upadacitinib was approved earlier for treatment of rheumatoid…

Med Lett Drugs Ther. 2025 Jul 21; 67(1733):114-5 doi:10.58347/tml.2025.1733b
The oral Janus kinase (JAK) inhibitor upadacitinib ( Rinvoq – Abbvie) has been approved by the FDA for treatment of giant cell arteritis. Upadacitinib was approved earlier for treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, nonradiographic axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease.
Issue 1702 · May 13, 2024
Sarilumab (Kevzara) for Polymyalgia Rheumatica

The FDA has approved the interleukin (IL)-6 inhibitor sarilumab ( Kevzara – Sanofi/Regeneron) for treatment of polymyalgia rheumatica (PMR) in adults who had an inadequate response to corticosteroids or…

Med Lett Drugs Ther. 2024 May 13; 66(1702):77-8 doi:10.58347/tml.2024.1702c
The FDA has approved the interleukin (IL)-6 inhibitor sarilumab ( Kevzara – Sanofi/Regeneron) for treatment of polymyalgia rheumatica (PMR) in adults who had an inadequate response to corticosteroids or cannot tolerate a corticosteroid taper. Sarilumab is the first biologic drug to be approved for treatment of PMR; it was previously approved for treatment of rheumatoid arthritis.
Issue 1679 · June 26, 2023 Free
In Brief: Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma (online only)

The FDA has approved lisocabtagene maraleucel ( Breyanzi – BMS) for treatment of adults with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade…

Med Lett Drugs Ther. 2023 Jun 26; 65(1679):e104-5 doi:10.58347/tml.2023.1679f
The FDA has approved lisocabtagene maraleucel ( Breyanzi – BMS) for treatment of adults with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, or follicular lymphoma grade 3B who have disease refractory to first-line chemoimmunotherapy, relapsed within 12 months of or after first-line chemoimmunotherapy, are not eligible for hematopoietic stem cell transplantation due to comorbidities or age, or have relapsed or refractory disease after ≥2 lines of systemic therapy. Breyanzi is an individualized cellular product prepared from the patient's own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. The CAR T-cell products axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) are also FDA-approved for treatment of large B-cell lymphoma.
Issue 1678 · June 12, 2023 Free
In Brief: Brexucabtagene autoleucel (Tecartus) for Acute Lymphoblastic Leukemia (online only)

Brexucabtagene autoleucel ( Tecartus – Kite) has been approved by the FDA for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It was previously approved…

Med Lett Drugs Ther. 2023 Jun 12; 65(1678):e105-6 doi:10.58347/tml.2023.1678f
Brexucabtagene autoleucel ( Tecartus – Kite) has been approved by the FDA for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It was previously approved for treatment of relapsed or refractory mantle cell lymphoma. Tecartus is an individualized cellular product prepared from the patients own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. The CAR T-cell immunotherapy tisagenlecleucel (Kymriah) was approved in 2017 for treatment of relapsed or refractory B-cell precursor ALL in patients ≤25 years old.
Issue 1677 · May 29, 2023 Free
COVID-19 Update: An EUA for Vilobelimab (Gohibic) for COVID-19

The investigational anti-complement component 5a (C5a) antibody vilobelimab ( Gohibic – InflaRx) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of hospitalized adults with…

Med Lett Drugs Ther. 2023 May 29; 65(1677):86-7 doi:10.58347/tml.2023.1677d
The investigational anti-complement component 5a (C5a) antibody vilobelimab ( Gohibic – InflaRx) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of hospitalized adults with COVID-19 beginning within 48 hours after invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) is started. Vilobelimab is the first anti-C5a antibody to become available in the US.
Issue 1667 · January 9, 2023 Free
COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only)

The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has been approved by the FDA for IV treatment of COVID-19 in hospitalized adults who are receiving a systemic corticosteroid…

Med Lett Drugs Ther. 2023 Jan 9; 65(1667):e9 doi:10.58347/tml.2023.1667d
The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has been approved by the FDA for IV treatment of COVID-19 in hospitalized adults who are receiving a systemic corticosteroid and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab was previously available for this indication under an Emergency Use Authorization (EUA); it remains available under an EUA for treatment of children 2-17 years old who are hospitalized with COVID-19 and require oxygen support.
Issue 1665 · December 12, 2022 Free
An EUA for Anakinra (Kineret) for COVID-19 (online only)

The recombinant interleukin-1 (IL-1) receptor antagonist anakinra ( Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19…

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):e203-4
The recombinant interleukin-1 (IL-1) receptor antagonist anakinra ( Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19 pneumonia who require low- or high-flow supplemental oxygen, are at risk of progressing to severe respiratory failure, and are likely to have elevated plasma levels of soluble urokinase plasminogen activator receptor (suPAR). Anakinra has been available in the US for years; it is FDA-approved for multiple indications, including rheumatoid arthritis. Assays for suPAR are not commercially available in the US.
Issue 1637 · November 15, 2021
Drugs for Rheumatoid Arthritis

Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were…

Med Lett Drugs Ther. 2021 Nov 15; 63(1637):177-84
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Issue 1637 · November 15, 2021
Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)

View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis

Med Lett Drugs Ther. 2021 Nov 15; 63(1637):e187-9
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Issue 1637 · November 15, 2021
Flowchart: Rheumatoid Arthritis Treatment (online only)

View the Flowchart: Rheumatoid Arthritis Treatment

Med Lett Drugs Ther. 2021 Nov 15; 63(1637):e1
View the Flowchart: Rheumatoid Arthritis Treatment
Issue 1629 · July 26, 2021 Free
An EUA for Tocilizumab (Actemra) for COVID-19

The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has received an Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2 years…

Med Lett Drugs Ther. 2021 Jul 26; 63(1629):113-4
The interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) has received an Emergency Use Authorization (EUA) from the FDA for IV treatment of COVID-19 in hospitalized patients ≥2 years old who are receiving a systemic corticosteroid and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Tocilizumab has been approved by the FDA for various indications, including rheumatoid arthritis and juvenile idiopathic arthritis.
Issue 1625 · May 31, 2021
Teprotumumab (Tepezza) for Thyroid Eye Disease

Teprotumumab-trbw ( Tepezza - Horizon), an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, has been approved by the FDA for IV treatment of thyroid eye disease. It is the first drug to be approved in…

Med Lett Drugs Ther. 2021 May 31; 63(1625):87-8
Teprotumumab-trbw ( Tepezza - Horizon), an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, has been approved by the FDA for IV treatment of thyroid eye disease. It is the first drug to be approved in the US for this indication.
Issue 1595 · April 6, 2020 Free
Some Drugs for COVID-19

The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in…

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):49-50
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking, but some recommendations can be made. For additional information on specific drugs, see our table Some Drugs Being Considered for Treatment of COVID-19.
Issue 1595 · April 6, 2020 Free
Table: Treatments Considered for COVID-19 (Archived) (online only)

View the Table: Treatments Considered for COVID-19

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):e1-289
View the Table: Treatments Considered for COVID-19
Issue 1919 · April 6, 2020 Free
Some Drugs for COVID-19

The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in…

Med Lett Drugs Ther. 2020 Apr 6; 62(1919):1 doi:10.58347/tml.2020.1919a
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking, but some recommendations can be made. For additional information on specific drugs, see our table Some Drugs Being Considered for Treatment of COVID-19.
Issue 1552 · July 30, 2018
Drugs for Rheumatoid Arthritis

Disease-modifying antirheumatic drugs (DMARDs) are used for initial treatment of rheumatoid arthritis (RA) to achieve clinical remission and prevent irreversible joint damage (see Table 1). DMARDs generally do…

Med Lett Drugs Ther. 2018 Jul 30; 60(1552):123-8
Disease-modifying antirheumatic drugs (DMARDs) are used for initial treatment of rheumatoid arthritis (RA) to achieve clinical remission and prevent irreversible joint damage (see Table 1). DMARDs generally do not have an immediate analgesic effect, but over time they can control symptoms and have been shown to delay and possibly stop progression of the disease. Methotrexate ( Trexall , and others) is generally the drug of choice; it can be used for patients with low, moderate, or high disease activity. For mild disease, some clinicians prefer to start with hydroxychloroquine ( Plaquenil , and generics) and/or sulfasalazine ( Azulfidine , and others).
Issue 1552 · July 30, 2018
Expanded Table: Biologic Agents for Rheumatoid Arthritis (online only)

View Expanded Table: Biologic Agents for Rheumatoid Arthritis

Med Lett Drugs Ther. 2018 Jul 30; 60(1552):e130-4
View Expanded Table: Biologic Agents for Rheumatoid Arthritis
Issue 1551 · July 16, 2018
Axicabtagene Ciloleucel (Yescarta) for B-Cell Lymphoma (online only)

The FDA has approved axicabtagene ciloleucel ( Yescarta – Kite) for treatment of adults with relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy. Yescarta is an…

Med Lett Drugs Ther. 2018 Jul 16; 60(1551):e122-3
The FDA has approved axicabtagene ciloleucel ( Yescarta – Kite) for treatment of adults with relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy. Yescarta is an individualized cellular product prepared from the patient's own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. It is the second CAR T-cell immunotherapy to become available in the US. Tisagenlecleucel (Kymriah ), a CAR T-cell product previously approved for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in patients ≤25 years old, was recently also approved for relapsed or refractory CD19+ large B-cell lymphoma after ≥2 lines of systemic therapy.
Issue 1530 · September 25, 2017
Tocilizumab (Actemra) for Giant Cell Arteritis

The FDA has approved the interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) for subcutaneous (SC) treatment of giant cell arteritis in adults. It is the first drug to be approved in…

Med Lett Drugs Ther. 2017 Sep 25; 59(1530):161-2
The FDA has approved the interleukin-6 (IL-6) receptor antagonist tocilizumab ( Actemra – Genentech) for subcutaneous (SC) treatment of giant cell arteritis in adults. It is the first drug to be approved in the US for this indication. Tocilizumab is also approved for treatment of rheumatoid arthritis, polyarticular or systemic juvenile idiopathic arthritis, and cytokine release syndrome.
Issue 1527 · August 14, 2017
Sarilumab (Kevzara) for Rheumatoid Arthritis

The FDA has approved the interleukin (IL)-6 inhibitor sarilumab ( Kevzara – Sanofi) for second-line treatment of adults with moderately to severely active rheumatoid arthritis (RA). It is the second IL-6…

Med Lett Drugs Ther. 2017 Aug 14; 59(1527):134-6
The FDA has approved the interleukin (IL)-6 inhibitor sarilumab ( Kevzara – Sanofi) for second-line treatment of adults with moderately to severely active rheumatoid arthritis (RA). It is the second IL-6 inhibitor to be approved for this indication; tocilizumab (Actemra) was approved earlier.
Issue 1458 · December 22, 2014
Drugs for Rheumatoid Arthritis

For initial treatment of rheumatoid arthritis, most expert clinicians prescribe a disease-modifying antirheumatic drug (DMARD) and add a nonsteroidal anti-inflammatory drug (NSAID) or a corticosteroid to…

Med Lett Drugs Ther. 2014 Dec 22; 56(1458):127-32
For initial treatment of rheumatoid arthritis, most expert clinicians prescribe a disease-modifying antirheumatic drug (DMARD) and add a nonsteroidal anti-inflammatory drug (NSAID) or a corticosteroid to control symptoms. Methotrexate is generally the DMARD of choice... DMARDs Disease-modifying antirheumatic drugs (DMARDs) are used early in the treatment of rheumatoid arthritis (RA) to achieve clinical remission, prevent irreversible damage to joints, and minimize toxicity associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. DMARDs generally do not have an immediate analgesic effect, but over time can control symptoms and have been shown to delay and possibly stop progression of the disease. Methotrexate ( Rheumatrex , and others) is generally the first DMARD prescribed; it can be used to treat mild, moderate, or severe RA. For mild disease, some clinicians prefer to start with hydroxychloroquine ( Plaquenil , and generics) and/or sulfasalazine ( Azulfidine , and others).
Issue 1423 · August 19, 2013
Canakinumab (Ilaris) for Systemic Juvenile Idiopathic Arthritis

The FDA has approved the interleukin-1 (IL-1) beta inhibitor canakinumab ( Ilaris – Novartis) for treatment of systemic juvenile idiopathic arthritis (sJIA; formerly called juvenile rheumatoid arthritis or…

Med Lett Drugs Ther. 2013 Aug 19; 55(1423):65-6
The FDA has approved the interleukin-1 (IL-1) beta inhibitor canakinumab ( Ilaris – Novartis) for treatment of systemic juvenile idiopathic arthritis (sJIA; formerly called juvenile rheumatoid arthritis or Still’s disease) in children ≥2 years old. Canakinumab was approved earlier for treatment of cryopyrin-associated periodic syndromes (CAPS). Tocilizumab (Actemra) , an interleukin-6 (IL-6) inhibitor that has been available since 2010 for treatment of rheumatoid arthritis in adults, was also recently approved by the FDA for sJIA. Canakinumab is the only IL-1 inhibitor approved for this indication.
Issue 1407 · January 7, 2013
Tofacitinib (Xeljanz) for Rheumatoid Arthritis

The FDA has approved tofacitinib (toe” fa sye’ ti nib; Xeljanz – Pfizer), an oral Janus kinase (JAK) inhibitor, for treatment of adults with moderately to severely active rheumatoid arthritis (RA) who…

Med Lett Drugs Ther. 2013 Jan 7; 55(1407):1-3
The FDA has approved tofacitinib (toe” fa sye’ ti nib; Xeljanz – Pfizer), an oral Janus kinase (JAK) inhibitor, for treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to or are intolerant of methotrexate. Ruxolitinib (Jakafi) is the only other JAK inhibitor available in the US; it is FDA-approved for treatment of myelofibrosis.
Issue 117 · May 1, 2012
Drugs for Rheumatoid Arthritis

Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to achieve clinical remission, prevent irreversible damage to joints, and minimize toxicity…

Treat Guidel Med Lett. 2012 May; 10(117):37-44
Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to achieve clinical remission, prevent irreversible damage to joints, and minimize toxicity associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. DMARDs (Table 1) generally do not have an immediate analgesic effect, but over time can control symptoms and have been shown to delay and possibly stop progression of the disease. NSAIDs have immediate analgesic and antiinflammatory effects, but may not affect the disease process. Oral corticosteroids can relieve joint symptoms and control systemic manifestations, but their chronic use can cause many complications. Judicious use of intra-articular corticosteroids can rapidly decrease inflammation in acute joints with few, if any, adverse effects.
Issue 1340 · June 14, 2010
Tocilizumab (Actemra) for Rheumatoid Arthritis

The FDA has approved tocilizumab ( Actemra – Genentech; RoActemra in Europe) for intravenous (IV) treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an…

Med Lett Drugs Ther. 2010 Jun 14; 52(1340):47-8
The FDA has approved tocilizumab ( Actemra – Genentech; RoActemra in Europe) for intravenous (IV) treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor (TNF) inhibitors.
Issue 81 · May 1, 2009
Drugs for Rheumatoid Arthritis

Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal…

Treat Guidel Med Lett. 2009 May; 7(81):37-46
Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.